BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Babic Z, Svoboda-Beusan I, Kucisec-Tepes N, Dekaris D, Troskot R. Increased activity of Pgp multidrug transporter in patients with Helicobacter pylori infection. World J Gastroenterol 2005; 11(18): 2720-2725 [PMID: 15884110 DOI: 10.3748/wjg.v11.i18.2720] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Zhang M. High antibiotic resistance rate: A difficult issue for Helicobacter pylori eradication treatment. World J Gastroenterol. 2015;21:13432-13437. [PMID: 26730153 DOI: 10.3748/wjg.v21.i48.13432] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 21] [Article Influence: 6.4] [Reference Citation Analysis]
2 Omar M, Crowe A, Parsons R, Ee H, Tay CY, Hughes J. P-glycoprotein expression in Helicobacter pylori-positive patients: the influence of MDR1 C3435T polymorphism. J Dig Dis. 2012;13:414-420. [PMID: 22788927 DOI: 10.1111/j.1751-2980.2012.00606.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
3 Sugimoto M, Furuta T, Shirai N, Kodaira C, Nishino M, Yamade M, Ikuma M, Sugimura H, Ishizaki T, Hishida A. MDR1 C3435T polymorphism has no influence on developing Helicobacter pylori infection-related gastric cancer and peptic ulcer in Japanese. Life Sci 2008;83:301-4. [PMID: 18644389 DOI: 10.1016/j.lfs.2008.06.022] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
4 Kim BJ, McDonagh MA, Deng L, Gastfriend BD, Schubert-Unkmeir A, Doran KS, Shusta EV. Streptococcus agalactiae disrupts P-glycoprotein function in brain endothelial cells. Fluids Barriers CNS 2019;16:26. [PMID: 31434575 DOI: 10.1186/s12987-019-0146-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
5 Dietz I, Jerchel S, Szaszák M, Shima K, Rupp J. When oxygen runs short: the microenvironment drives host-pathogen interactions. Microbes Infect 2012;14:311-6. [PMID: 22133978 DOI: 10.1016/j.micinf.2011.11.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
6 Abdel-rahman SM, Amidon GL, Kaul A, Lukacova V, Vinks AA, Knipp GT. Summary of the National Institute of Child Health and Human Development–Best Pharmaceuticals for Children Act Pediatric Formulation Initiatives Workshop–Pediatric Biopharmaceutics Classification System Working Group. Clinical Therapeutics 2012;34:S11-24. [DOI: 10.1016/j.clinthera.2012.09.014] [Cited by in Crossref: 49] [Cited by in F6Publishing: 28] [Article Influence: 6.1] [Reference Citation Analysis]